Profound Medical names senior finance executive, Steve Forte, to board

Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee.

Most recently, Mr. Forte was CFO of Clementia Pharmaceuticals (NASDAQ:CMTA), which was acquired by Ispen S.A. for $1.3-billion in April 2019.

Before joining Clementia, Mr. Forte was CFO of Thinking Capital Financial, a leading financial technology firm. He also served for nearly a decade at Aptalis Pharma, where he was responsible for the overall corporate controllership of a company with $700-million in annual revenue, six operating companies, five manufacturing sites and 40 subsidiaries. Mr. Forte also led Aptalis’ preparations for a U.S. IPO prior to its sale to Forest Labs for $2.9-billion.

In a statement, Brian Ellacott, lead independent director of Profound, said not only is Mr. Forte an experienced financial executive in the life science industry, but he also has a “breadth of relevant NASDAQ listing and M&A experience that could prove to be invaluable as Profound executes the next stages of its growth strategy.”

Profound is the only company to provide customized, incision-free therapies, which combine real-time MRI, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. Profound’s lead products are TULSA-PRO for both malignant and benign prostate disease, and Sonalleve, which is currently targeting uterine fibroids and palliative pain. TULSA-PRO is CE marked and Profound’s FDA 510(k) application for the device is currently undergoing a substantive review by the Agency. Sonalieve is CE marked and has also been approved by the China FDA for the non-invasive treatment of uterine fibroids.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.